-
BRVE share price: currently unavailable. Sorry, we currently don't have enough data to create an insight.
-
Price change
The price of BRVE shares has decreased $4.18 since the market last closed. This is a 14.32% drop.
-
Last closed at $25.02.
The stock has since risen $0.47 in pre-market trading.
Key terms
About BRVE
Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.
-
Market cap: $2.25B
A market capitalization between $2 billion and $10 billion places BRVE in the mid-capitalization category.
Key terms
Smart score
Latest BRVE news
BRVE Financials
-
BRVE total_revenue: currently unavailable. Sorry, we currently don't have enough data to create an insight.
-
BRVE net income: currently unavailable. Sorry, we currently don't have enough data to create an insight.
-
BRVE earnings per share: currently unavailable. Sorry, we currently don't have enough data to create an insight.
Key terms
BRVE Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
BRVE Competitors
-
How competitors are chosen
BRVE's competitors are included in the Health Technology sector and Pharmaceuticals: Major group
-
Market cap: $2.25B
A market capitalization between $2 billion and $10 billion places BRVE in the mid-capitalization category.
